APUS vs FFIV · $2.4M cap vs P/E 32, rev $3.09B
Apimeds Pharmaceuticals US, Inc. (APUS) versus F5 Networks Inc (FFIV) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
F5 Networks Inc (FFIV) is a software - infrastructure company listed on NASDAQ.
APUS does not have a complete income-statement cache yet.
Latest reported FFIV revenue for 2025-09-30 was $3.09B. Net income was $692.4M. FFIV currently screens at market cap $21.71B and trailing P/E 31.6.
APUS currently screens at market cap $2.4M. FFIV currently screens at market cap $21.71B and trailing P/E 31.6.
Not investment advice. Open the APUS and FFIV stock pages for the full models.
Not investment advice.